Drug Shortage Report for TRILEPTAL 300 MG
Report ID | 175426 |
Drug Identification Number | 02242068 |
Brand name | TRILEPTAL 300 MG |
Common or Proper name | TRILEPTAL 300MG 5X10 |
Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | OXCARBAZEPINE |
Strength(s) | 300MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 5x10 |
ATC code | N03AF |
ATC description | ANTIEPILEPTICS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2022-11-25 |
Actual start date | 2023-01-19 |
Estimated end date | 2023-01-31 |
Actual end date | 2023-02-03 |
Shortage status | Resolved |
Updated date | 2023-04-13 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v5 | 2023-04-13 | French | Compare |
v4 | 2023-04-13 | English | Compare |
v3 | 2022-11-26 | English | Compare |
v2 | 2022-11-22 | French | Compare |
v1 | 2022-11-22 | English | Compare |
Showing 1 to 5 of 5